04 Jun 2026 17:07 UTC
“To scale, the gray-market peptide trade adopted cryptocurrency as its backbone,” Chainalysis said in a report.
➤ Concerns exist regarding product safety, with reduced spending on purity testing and potential links to organizations involved in illicit drug sales, often targeting inexperienced buyers.
➤ This trend is driven by the popularity of GLP-1 drugs and the avoidance of traditional banking systems by suppliers, leading to a more professionalized on-chain approach by top vendors.
➤ The gray market peptide trade is increasingly relying on Bitcoin and stablecoins for transactions, with a 159% quarter-over-quarter increase in crypto value flowing into the sector.
Quick Take
• The “concentrated cluster of top-tier vendors” that Chainalysis observed when analyzing the growing gray market peptide sector often relies on bitcoin and stablecoins, according to a new report.
• Q1 saw a 159% quarter-over-quarter jump in the value of crypto flowing into the sector to $32 million.
• Chainalysis says the gray-market peptide sector has surpassed a $100 million annual run rate, with first-quarter 2026 sales jumping 159% quarter over quarter to $32 million from $12 million.
• Demand is being fueled by online trends and the popularity of GLP-1 drugs like Ozempic and Wegovy, while suppliers increasingly use crypto because banks and card processors avoid the trade.
• Top vendors are becoming more professional on-chain, relying mainly on bitcoin and stablecoins, with larger orders skewing toward stablecoins to reduce volatility risk.
• Chainalysis also found safety concerns, as spending on independent purity testing fell to an estimated $8 per buyer even as the overall number of buyers rose sharply.
• Some suspected fentanyl-linked organizations are shifting into peptides, and the market often targets inexperienced buyers unfamiliar with both unregulated pharmaceuticals and cryptocurrency.
As the semi-legal peptide sector explodes, driven by a confluence of online trends like "looksmaxing" and the "Make America Healthy Again" movement, more and more suppliers and buyers are turning to cryptocurrency, Chainalysis said Thursday in a new report.
According to the analysis firm, the appetite for off-label peptides — the building blocks of proteins used as a dietary supplement, and across the health, wellness, and fitness spaces — has surged past a $100 million annual run rate. The first quarter of 2026 alone saw a 159% quarter-over-quarter jump to $32 million from $12 million, according to Chainalysis' report.
What started as a niche interest among biohackers has entered the public conversation, primarily driven by the success of GLP-1 peptide drugs like Ozempic and Wegovy, leading to search interest for other solutions that can be used for anything from suppressing appetite to repairing cell damage.
And like the other so-called research chemical "gray market," where derivatives of illicit drugs like fentanyl are sold online often via crypto, the peptide trade is increasingly dominated by Chinese chemical manufacturers, which are often cut off from the traditional banking sector, according to Chainalysis.
"This demand has given rise to ‘gray market’ peptides and a network of overseas suppliers selling raw, unbranded products directly to buyers at a fraction of the pharmacy price," Chainalysis said. "But because traditional banks and credit card processors often prohibit the sale of prescription-grade compounds and unregulated substances, much of this industry operates outside the standard financial system."
"To scale, the gray-market peptide trade adopted cryptocurrency as its backbone," Chainalysis analysts wrote.
According to Chainalysis, the "concentrated cluster of top-tier vendors" that supply much of the peptide market have begun to "exhibit a more professionalized approach to on-chain finance," and often rely on bitcoin and stablecoins.
"When isolating vendors that average $1,000 or more per deposit, the asset mix shifts heavily toward majority stablecoins — a potentially calculated move to insulate massive supply chain orders from the unpredictable price fluctuations of the broader crypto market," Chainalysis wrote.
Safety concerns
The onchain footprint around the emerging peptide sector also revealed that as more buyers are making purchases with crypto, a smaller percentage appears to be also paying to quality test these unregulated substances. According to Chainalysis, before the recent bump in sales, many wallets buying peptides from China frequently also transacted with the independent chemical purity testing company Janoshik, in Czechia.
However, "testing spend crashed by an estimated 88% to just $8 per buyer," even though "Janoshik is actually testing more than ever before," Chainalysis said, due to the sheer rise in the number of buyers.
Chainalysis notes that some organizations accused of selling fentanyl and other drugs appear to be shifting to or expanding into peptides. For instance, Shanghai Sigma Audley, a supplier with suspected connections to transnational drug cartels, had brought in at least $1 million in bitcoin and $3.59 million in stablecoins by selling fentanyl precursors before shifting to peptides, Chainalysis said.
Chainlysis notes that this growing sector often "targets a vulnerable demographic inexperienced with both unregulated pharmaceuticals and cryptocurrency."
Categories rationale: The article discusses the use of Bitcoin and stablecoins (asset-types: stablecoins-digital-cash) in a semi-legal trade, highlighting the challenges with traditional financial systems and the potential for regulatory scrutiny or enforcement actions (legal-regulatory: enforcement-actions-litigation). The use of these cryptocurrencies implies a blockchain settlement layer, with Bitcoin and stablecoins commonly transacted on EVM-compatible chains (blockchain-usage: ethereum-evm-l1s).Characteristics justification: The article discusses a 'gray market' and potential links to illicit activities like fentanyl sales, indicating negative sentiment. The rapid growth and shift to crypto suggest a degree of novelty and uncertainty in the market. The focus on 'top-tier vendors' and their 'professionalized approach' suggests a degree of relevance to market participants. The mention of safety concerns and targeting inexperienced buyers contributes to a negative sentiment score.Tag relevance: The tags 'gray market peptides', 'chainalysis', 'bitcoin', 'stablecoins', and 'cryptocurrency' are central to the article's topic. 'Ozempic' and 'Wegovy' are mentioned as drivers of demand. 'Fentanyl' highlights the association with illicit markets. 'On-chain finance' describes the operational shift, and 'unregulated pharmaceuticals' defines the product category.asset-types: stable_coin
rwa: true
entropy: 0.75
sentiment: -0.6
staleness: 0.3
relevance: 0.8
uncertainty: 0.5RWATimes slug: theblock-chainalysis-says-top-tier-gray-market-peptide-vendors-turn-to-bitcoin-and-stablecoins-766739808